With User Inspired Features and a Redesigned Interface, Oncomine Remains Data-Focused
ANN ARBOR, Mich., March 26 /PRNewswire-USNewswire/ -- Compendia Bioscience announces the release of Oncomine Concepts Edition version 4.0, the latest incarnation of the company's flagship product. Since its inception at the University of Michigan, Oncomine has been rapidly adopted by drug discovery and development organizations looking to improve results of cancer drug development efforts. This new version of Oncomine features an improved user-interface and new export function that allows results sharing.
Cancer researchers and drug developers have made Oncomine the industry-standard, with 15 of the top 20 cancer research companies using this product for interactive access and in-depth analysis of curated cancer genomics data. Oncomine has led to several major cancer research discoveries such as the presence of gene fusions in the majority of prostate cancers (Cancer Cell, Volume 13 Issue 6: June 2008. Nature, Aug 2 2007).
"In accumulating so much high-value data, our biggest success has created our biggest challenge," commented Compendia CEO and Co-founder Dan Rhodes, Ph.D. "It has become difficult to navigate all of the data and analyses to answer the burning questions at hand. Oncomine Concepts Edition 4.0 makes these efforts more intuitive and much, much easier."
New Functionality in Oncomine Concepts Edition 4.0
While improved user experience was the driving force in Oncomine Concepts Edition 4.0, the entire Oncomine database was also scrutinized in an effort to standardize and catalog all data points. Oncomine Research Edition 4.0 will be released in the later part of 2009.
About Compendia Bioscience, Inc.
Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. www.compendiabio.com
Oncomine combines a rapidly growing compendium of 30,000+ expertly curated cancer genomic profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. http://www.compendiabio.com/products/products.htm
CONTACT: John Freshley, Chief Business Officer of Compendia Bioscience,
Web site: http://www.compendiabio.com/